Condition

Eosinophilic Asthma

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 29 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials29
Recruiting3
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

29 shown
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaNCT07323654 · 2026-01-28
RECRUITING
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentNCT06750289 · 2025-03-28
RECRUITING
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing EosinophilsNCT04538937 · 2020-02-26
RECRUITING
Fasenra: An Asthma StudyNCT07654842 · 2026-07-01
ENROLLING_BY_INVITATION
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic AsthmaNCT07250594 · 2025-12-01
NOT_YET_RECRUITING
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPANCT07343661 · 2025-10-17
ENROLLING_BY_INVITATION
Eosinophil Subpopulations in Eosinophilic-associated DiseasesNCT06911775 · 2025-04-01
NOT_YET_RECRUITING
Phase III Long-Term Extension Study With DexpramipexoleNCT06388889 · 2024-06-12
TERMINATED
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic AsthmaNCT05985694 · 2023-11-27
COMPLETED
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)NCT05813288 · 2023-03-27
TERMINATED
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.NCT05763121 · 2023-01-30
TERMINATED
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic AsthmaNCT05748600 · 2023-01-30
ACTIVE_NOT_RECRUITING
Effect of Mepolizumab on Severe Eosinophilic AsthmaNCT04641741 · 2021-04-01
UNKNOWN
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for AsthmaNCT05002621 · 2021-02-16
COMPLETED
XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial AsthmaNCT04674137 · 2020-12-16
COMPLETED
Identification of Autoantigens in EGPA and Severe Eosinophilic AsthmaNCT04671446 · 2020-12-10
COMPLETED
Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and AsthmaNCT05398133 · 2020-09-01
UNKNOWN
Eosinophils Endotypes in Chronic Airway Inflammatory DiseasesNCT04187976 · 2020-03-03
COMPLETED
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in BrazilNCT04228588 · 2020-01-09
UNKNOWN
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic AsthmaNCT04046939 · 2019-08-15
COMPLETED
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".NCT04585997 · 2018-11-03
UNKNOWN
Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe AsthmaNCT03563521 · 2017-11-27
COMPLETED
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic AsthmaNCT03469934 · 2017-11-14
COMPLETED
Intense Airway Eosinophilia in AsthmaNCT03696914 · 2017-06-06
COMPLETED
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe AsthmaNCT01508936 · 2012-02-01
COMPLETED
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic AsthmaNCT01290887 · 2011-06-01
TERMINATED
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic AsthmaNCT01287039 · 2011-04-01
COMPLETED
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic AsthmaNCT01285323 · 2011-03-01
COMPLETED
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic AsthmaNCT01270464 · 2011-02-01
COMPLETED

Common interventions

PlaceboDRUG11ReslizumabDRUG5Dexpramipexole DihydrochlorideDRUG4AD17002DRUG1AD17002BIOLOGICAL1Autoantibody ELISADIAGNOSTIC_TEST1benralizumabCOMBINATION_PRODUCT1BenralizumabDRUG1Budesonide-albuterolDRUG1DexpramipexoleDRUG1EtokimabBIOLOGICAL1Formulation bufferOTHER1Granulocyte ImmunofluorescenceDIAGNOSTIC_TEST1ICS-LABACOMBINATION_PRODUCT1KT-621DRUG1MepolizumabDRUG1Mepolizumab 100 MGDRUG1Mepolizumab 100 MG [Nucala]DRUG1Mepolizumab 100 MG Injection [Nucala]DRUG1Mepolizumab 300 mgDRUG1no interventionOTHER1ObservationalOTHER1OmalizumabDRUG1PlaceboOTHER1Placebo for BenralizumabCOMBINATION_PRODUCT1

Trial status mix

COMPLETED13
TERMINATED4
UNKNOWN4
RECRUITING3
ENROLLING_BY_INVITATION2
NOT_YET_RECRUITING2
ACTIVE_NOT_RECRUITING1

Phase mix

PHASE310
PHASE26
PHASE44
PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.